Investment Rating - The report maintains an "Outperform" rating for the industry [2]. Core Insights - The third-generation EGFR TKI has become the first-line standard therapy for advanced EGFR mutation NSCLC, significantly extending median progression-free survival (mPFS) to 18.9-22.1 months compared to earlier generations [4][24]. - The domestic EGFR TKI market is expected to exceed 20 billion CNY in 2024, with third-generation EGFR TKIs accounting for 88% of the market share [4][30]. - There is an urgent need to address resistance mechanisms following third-generation EGFR TKI treatment, with ongoing exploration of fourth-generation TKIs, bispecific antibodies, and antibody-drug conjugates (ADCs) [5][32]. Summary by Sections 1. High Incidence of Lung Cancer in China - Lung cancer is the most common malignant tumor globally, with approximately 2.6 million new cases expected in 2024, including about 1.15 million in China [8]. - Non-small cell lung cancer (NSCLC) accounts for around 85% of lung cancer cases, with adenocarcinoma and squamous cell carcinoma being the most prevalent subtypes [8]. 2. Third-Generation EGFR TKI as First-Line Therapy - The third-generation EGFR TKI has established itself as the first-line treatment for advanced EGFR mutation NSCLC, with significant improvements in mPFS compared to first and second generations [4][16][24]. - The report highlights the efficacy of third-generation TKIs in overcoming common mutations and their favorable safety profile [4][24]. 3. Exploration of Resistance Mechanisms - The report discusses the complexity of resistance mechanisms to third-generation EGFR TKIs, including both EGFR-dependent and independent pathways [5][32]. - Current research focuses on developing fourth-generation TKIs targeting specific mutations and exploring combination therapies with bispecific antibodies and ADCs [5][32][39]. 4. Investment Recommendations - The report emphasizes the growth potential of third-generation EGFR TKIs and suggests monitoring companies like Hansoh Pharma and Eli Lilly for market penetration and sales growth [51]. - It also highlights the progress of ADCs and bispecific antibodies in clinical trials, indicating a robust pipeline for future treatments [51][52].

Group 1: Federal Reserve and Market Expectations - Goldman Sachs indicates that the Federal Reserve is expected to lower interest rates during the December 9-10 meeting, with a nearly certain probability of a 25 basis point cut at around 85%-86% [1] Group 2: Company Developments - Baillie Gifford's subsidiary SystImmune received a $250 million milestone payment from Bristol-Myers Squibb related to the global strategic collaboration agreement, with potential for up to $2.5 billion in near-term or contingent payments and an additional $7.1 billion upon achieving specific development, registration, and sales milestones [1] - Innovent Biologics announced that its self-developed drug, Xinmeiyue® (Pikankizumab injection), has been approved by the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis in adult patients, marking a significant advancement in domestic precision treatment for psoriasis [1] Group 3: Market Performance and Trends - The Hong Kong Stock Connect Innovation Drug ETF (159570) experienced a decline of over 1% for two consecutive days, with a trading volume exceeding 1 billion yuan, and a net inflow of 80 million yuan during the day [3] - As of November 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) exceeded 24 billion yuan, leading its peers in the same category [3] Group 4: Upcoming Events and Industry Catalysts - The results of the drug catalog negotiation conducted by the Medical Insurance Bureau are expected to be released in the first weekend of December, with a focus on the inclusion of domestic biological innovative drugs for skin diseases in the medical insurance [4] - The American Society of Hematology (ASH) conference is set to take place from December 6-9, where multiple differentiated hematology products will have data disclosed, with a focus on companies like BeiGene, Innovent Biologics, and others [4] Group 5: Company Stock Performance - The weighted stocks of the Hong Kong Stock Connect Innovation Drug ETF (159570) showed mixed performance, with major stocks like Rongchang Bio down over 5%, while Innovent Biologics and Hansoh Pharmaceutical saw slight increases [1][2]

Investment Rating - The industry investment rating is "Outperform the Market" [1][31]. Core Viewpoints - The report highlights the initiation of centralized procurement for electrophysiology and neuro-interventional medical consumables in Beijing, which is expected to promote the entry of domestic high-end products and accelerate domestic substitution [4]. - The procurement covers all public medical institutions in Beijing, with a two-year agreement period, and includes various categories of electrophysiology and neuro-interventional products [4]. - The report suggests focusing on leading companies with comprehensive layouts in the electrophysiology field, such as Huatai Medical and Microelectrophysiology [4]. Summary by Sections Industry Overview - The centralized procurement for electrophysiology and neuro-interventional consumables has officially started, with a deadline for submission set for December 1 [4]. - The procurement is led by six top-tier hospitals in Beijing and aims to enhance the availability of domestic products [4]. Investment Strategy - The report recommends attention to innovative drug companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China Biopharmaceuticals [6]. - It also highlights companies with significant single-product potential and those leading in advanced technology platforms [6]. Market Performance - The pharmaceutical sector saw a 2.67% increase last week, outperforming the CSI 300 index, which rose by 1.64% [9][20]. - In the Hong Kong market, the pharmaceutical sector increased by 3.85%, leading among 11 sectors [30]. Notable Industry News - Abbott announced a $21 billion acquisition of Exact Sciences, enhancing its position in the cancer diagnostics field [13]. - Johnson & Johnson is acquiring Halda Therapeutics for $3.05 billion, focusing on prostate cancer treatments [14]. - A significant ophthalmic drug has been approved for market release, expanding treatment options for age-related macular degeneration [16]. - Novartis received approval for its oral drug Remibrutinib in China, targeting chronic spontaneous urticaria [17].

Core Insights - A paradigm shift in cancer treatment is underway, driven by combination therapies rather than single-agent treatments, as highlighted by Pfizer's strategy to focus on ADC combinations instead of direct comparisons with standard treatments or placebos [1][20] - Combination therapies are emerging as a significant trend in innovative drug development, addressing the limitations of single-agent therapies, such as low response rates and inevitable resistance [1][2] Group 1: Advantages of Combination Therapies - Combination therapies enhance efficacy and response rates, delay the onset of resistance, and maintain durable anti-tumor activity, significantly improving clinical value [2][3] - A notable example is the combination of Osimertinib with chemotherapy, which significantly extended the overall survival (OS) of patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) [2] Group 2: Market Dynamics and Competitive Landscape - The pharmaceutical industry is experiencing a "combination competition" era, where various combination strategies are being employed across different disease areas, leading to synergistic effects [7][20] - AstraZeneca's Osimertinib, despite being a top-selling drug, faces challenges from competitors and is implementing a comprehensive combination strategy to maintain its market position [5][6] Group 3: Ongoing Research and Development - Numerous clinical trials are underway exploring various combination therapies, including PD-(L)1 inhibitors with chemotherapy and other agents, indicating a robust pipeline in the oncology sector [14][19] - The exploration of combination therapies is not limited to solid tumors; significant advancements are also being made in hematological malignancies, showcasing the broad applicability of this approach [10][12] Group 4: Future Directions - The current landscape of drug development suggests that combination therapies will reshape the research and commercial ecosystem of the pharmaceutical industry, emphasizing the need for companies to adapt to this trend to remain competitive [20]

Core Insights - The report emphasizes the potential for a year-end market rally in Hong Kong stocks, driven by domestic policy support and expectations for a "New Year" market [1][2] - Key focus areas include the upcoming Central Economic Work Conference and the Federal Reserve's December meeting, which will influence market sentiment and liquidity conditions [2][3] Market Overview - The Hang Seng Index closed at 25,946, reflecting a year-to-date increase of 29.15% [4] - Southbound capital inflows have reached a historical high for the year, with a shift towards resilient growth sectors [1][4] - The current price-to-earnings ratio of the Hang Seng Index is near historical averages, suggesting favorable conditions for upward movement in the market [1] Key Variables to Monitor - The Central Economic Work Conference's announcements regarding deficit rates and consumption stimulus policies will be crucial for market risk appetite [2] - The Federal Reserve's December meeting will determine whether the last interest rate cut of the year will occur, with market expectations divided between a pause or further cuts [2] - Year-end portfolio adjustments by institutions may lead to increased volatility in certain sectors due to liquidity constraints [2] Tactical Positioning - The report suggests a tactical increase in exposure to sectors that are expected to benefit from policy expectations and year-end positioning [3] - Recommended stocks for December include: - Prosperity Industrial Trust (778 HK) - NVIDIA (NVDA US) - Shenzhou International (2313 HK) - Sungrow Power Supply (300274 CH) [3]

来源：市场资讯 （来源：化妆品观察 品观） 本周美妆行业发生了这些值得关注的事情 屈臣氏或港英双重上市 据外媒披露，长江和记正计划分拆屈臣氏集团，拟最早于2026年上半年在香港与伦敦两地双重上市，募 资规模约20亿美元（约合人民币141.5亿元），估值有望突破300亿美元（约合人民币2123亿元）。 •屈臣氏或港英双重上市 • 植物医生推进IPO • 国货防脱第一股要来了 • 珀莱雅原料商重返新三板 • 10亿级原料商格林生物三冲IPO • Hourglass创始人再推新品牌Outside In • 第六届中国化妆品年会圆满闭幕 IPO 若顺利上市，这将成为港股消费零售板块近年最大规模的IPO之一。对此，长和方面回应"不评论市场 传闻"。 作为拥有超16900家门店、1.75亿会员的全球零售巨头，屈臣氏如今的财务表却难掩疲态，尤其在中国 市场。2024年，屈臣氏中国区营业利润暴跌130%；2025年上半年收益同比下滑3%，门店净关闭145 家，成全球唯一负增长区域。 为扭转颓势，屈臣氏近年已推行"O+O"云店模式、试水社区店与大健康店、去BA化、降低自有品牌比 例、换血管理层等一系列自救举措，一定程度上延缓颓 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [3][43]. Core Views - The report emphasizes the potential of innovative drugs as the main investment theme for the year, with a focus on manufacturing overseas and aging-related consumption as relatively undervalued assets [13][31]. - The Chinese pharmaceutical industry has completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth avenues for Chinese pharmaceutical companies [31][32]. Summary by Sections UBT251 and Federal Pharmaceuticals - UBT251, a long-acting GLP-1/GIP/GCG agonist developed by Federal Pharmaceuticals, shows promising clinical results and potential in overseas markets [8][9]. - The global sales of Semaglutide are projected to exceed $30 billion in 2025, indicating a robust market for GLP-1 drugs [7][9]. - Federal Pharmaceuticals has signed an exclusive licensing agreement with Novo Nordisk for UBT251, which could align with the patent expiration of Semaglutide in 2032 [8][9]. Industry Performance - The pharmaceutical index rose by 2.67% from November 24 to November 28, outperforming the CSI 300 index by 1.03% [4][13]. - A total of 419 stocks in the sector increased in value, while 49 stocks declined during the same period [4][17]. Key Investment Opportunities - Recommended stocks include innovative drug companies such as Xinlitai, Zai Lab, and Federal Pharmaceuticals, as well as companies with improving performance like WuXi AppTec and Kairos Pharma [4][35]. - The report suggests focusing on sectors with stable operations and low valuations that are expected to see fundamental changes in 2026 [4][31]. Market Trends - The report highlights the increasing importance of aging populations and chronic disease management, which are driving demand in the healthcare sector [31][34]. - The ongoing development of AI technologies is expected to create new growth opportunities within the pharmaceutical industry [31][34].

证 券 研 究 报 告 行业周报 关注吸入制剂在呼吸疾病领域的突破 医药行业周报 投资评级： 报告日期： 推荐 （ 维持 ） 2025年11月30日 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 在呼吸疾病领域，如IPF、COPD等，吸入制剂+新靶点组合正取得更多积极的治疗效果。2025年6月10日，Insmed公布其 治疗PAH(肺动脉高压）新药TPIP（曲前列环素棕榈醇吸入粉剂）的临床2b期顶线数据，安慰剂校正的PVR较基线降低35%， LS均值比0.65（p＜0.001）。其冻干粉制剂的设计，不仅实现了用药的方便性，只需每日一次，而且治疗效果也优于曲前 列环素的口服品种。7月9日，默沙东宣布收购一家专注于呼吸系统疾病的生物制药公司Verona Pharma，总交易价值约为 100亿美元。通过此次收购，默沙东将获得一款用于治疗慢性阻塞性肺病（COPD）的重磅新药Ohtuvayre（恩司芬群）， 这是一种针对磷酸二酯酶3和4（PDE3和PDE4）的首创选择性双重抑制剂。FDA于2024年6月批准Ohtuvayre用 ...

Investment Rating - The report maintains an investment rating of "Outperform" [5] Core Insights - The innovative drug sector is experiencing rapid growth, with several new drugs being quickly incorporated into the medical insurance directory as of October 2025 [3][20] - The report highlights significant increases in the number of drugs entering hospitals, particularly those newly included in the insurance directory, indicating strong market demand [3][19] Weekly New Drug Market Review - From November 24 to November 30, 2025, the top five performing new drug companies were: Frontline Bio (+23.12%), Yifang Bio (+15.74%), Rongchang Bio (+15.39%), Kangfang Bio (+14.86%), and Jakes (+14.18%). The five companies with the largest declines were: Yongtai Bio (-4.11%), Nothland (-3.33%), Junshengtai (-2.78%), Boan Bio (-2.09%), and Dongyao Pharma (-1.11%) [1][14] Suggested Focus Stocks - The report suggests focusing on several companies with promising catalysts, including: 1. Companies with MNC certification and high overseas sales potential: Sanofi, Lianbang Pharma, and Kelun Biotech 2. Companies with overseas data catalysts: Betta Pharma, Hutchison China MediTech, and Yimeng Bio 3. Potential heavyweights for overseas MNC licensing: Fuhong Hanlin, Shiyao Group, and Yifang Bio 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat reduction and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][18] New Drug Industry Key Analysis - The National Healthcare Security Administration updated the data on innovative drugs included in the insurance directory as of October 2025, showing rapid hospital entry for several newly included domestic innovative drugs. Notable drugs with fast entry rates include: - Hengrui Medicine's Tazobactam - Innovent Biologics' Toripalimab - Haisco's Alogliptin and Clopidogrel - Sinopharm's Aliskiren and Amlodipine - Shanghai Yizhong's Paclitaxel polymer micelles - Kangfang Bio's Ivoris monoclonal antibody [3][19] New Drug Approval and Acceptance Status - This week, 11 new drugs or new indications received approval for market entry, while 13 new drugs or new indications were accepted for review [4][24] New Drug Clinical Application Approval and Acceptance Status - This week, 54 new drug clinical applications were approved, and 44 new drug clinical applications were accepted [8][27]

Market Overview - The Hang Seng Index opened high but experienced a decline, closing down 0.24% by midday [1] - The internet sector showed the strongest performance, followed by technology and consumer sectors, while healthcare and banking sectors faced declines [1] Internet Sector - The internet sector opened slightly higher and maintained a narrow range above the midline, rising 0.57% by midday [3] - Notable performers included Horizon Robotics with a 3.31% increase, while companies like JD Group, Baidu, and Alibaba also saw slight gains [3] - Conversely, stocks such as Bilibili, Kuaishou, and Meituan experienced minor declines [3] Consumer Sector - The consumer sector opened high but fell back, showing a slight increase of 0.07% by midday [3] - Significant gains were observed in Pop Mart, which surged 3.84%, and MGM, which rose 3.3%, with several other stocks like Mixue Ice City and金沙江 also increasing by over 2% [3] - However, Hansoh Pharmaceutical dropped 3.17%, and other companies like Nongfu Spring, Sinopharm, and Alibaba Health saw declines exceeding 2% [3] Healthcare Sector - The healthcare sector experienced a sharp decline after opening, maintaining a weak consolidation at low levels, down 0.96% by midday [3] - WuXi Biologics faced a significant drop of 3.9%, with nearly 10 stocks including CanSino Biologics, JD Health, and 3SBio also declining by over 1% [3]